5-Hydroxytryptamine and thromboxane A2 in ischaemic heart disease.
Platelet-derived 5-hydroxytryptamine and thromboxane A2 activate vascular smooth muscle cells, blood platelets and myocardial cells, both directly and through mutual amplification. Such an activation triggers: (1) vascular smooth muscle cell mitogenic activity, connective tissue synthetic activity and contractile activity; (2) platelet aggregation, secretion and procoagulant activity; (3) myocardial rhythm disturbances and necrosis. By such mechanisms, these autocoids contribute to arterial vessel wall proliferation, vasospasms and arterial thrombus formation in response to interactions of platelets with a damaged vessel wall, reduce the efficacy of thrombolytic agents and modulate myocardial reperfusion injury. Compounds directed specifically against these autocoids thus may offer possibilities for treating human ischaemic heart disease.
De Clerck
F
F
Department of Haematology, Medicinal Chemistry and Pharmacology, Janssen Research Foundation, Beerse, Belgium.
Janssen
P A
PA
D001095:Arachidonic Acids / Q000502:physiology; D001792:Blood Platelets / Q000502:physiology; D002478:Cells, Cultured / Q000187:drug effects; D003327:Coronary Disease / Q000209:etiology*; D006801:Humans; D009131:Muscle, Smooth, Vascular / Q000502:physiology*; D011985:Receptors, Serotonin / Q000502:physiology; D012701:Serotonin / Q000494:pharmacology / Q000502:physiology*; D013928:Thromboxane A2 / Q000494:pharmacology / Q000502:physiology*
D001095:Arachidonic Acids; D011985:Receptors, Serotonin; D012701:Serotonin; D013928:Thromboxane A2